Trial Profile
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms ASCENT
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 08 Jul 2022 Planned End Date changed from 1 Jun 2034 to 15 Nov 2031.
- 08 Jul 2022 Planned primary completion date changed from 1 Jan 2024 to 15 Nov 2023.